Antiretroviral Therapy for Acute and Chronic HIV Infection

Who is this study for? Patients with acute and chronic HIV infection
What treatments are being studied? HAART
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais').

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old

• Enrolled in the SEARCH 010 or 013 protocols with documentation of acute or chronic protocol defined HIV-1 infection and chooses to initiate or continue ART

• Understand the study and sign informed consent form. Persons who cannot read will have the consent form read and explained to them by a member of the study staff and they can give informed consent by using their thumb print

• Availability for follow-up for the planned study duration

Locations
Other Locations
Thailand
Institute of HIV Research and Innovation
RECRUITING
Bangkok
Contact Information
Primary
Nitiya Chomchey, RN, PhD
nitiya.c@searchthailand.org
66 82 899 4433
Backup
Tassanee Luekasemsuk, MSc
tassanee.l@searchthailand.org
Time Frame
Start Date: 2009-05-13
Estimated Completion Date: 2033-06
Participants
Target number of participants: 900
Treatments
Other: HAART
The proposed HAART regimen consists of:~* 1 or 2 nucleoside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications plus~* Dolutegravir(DTG) 50 mg orally once daily
Related Therapeutic Areas
Sponsors
Collaborators: ViiV Healthcare
Leads: SEARCH Research Foundation

This content was sourced from clinicaltrials.gov